Tectonic Therapeutic (TECX) Expected to Announce Earnings on Thursday

Key Points

• Tectonic Therapeutic (TECX) will announce its Q2 2025 earnings on August 13th, with analysts expecting a loss of ($0.98) per share.
• The company's stock has seen a price change with a 12-month range between $13.70 and $61.07, currently opening at $22.53.
• Institutional investors have significantly increased their stakes in Tectonic Therapeutic, with notable increases from firms like Jane Street Group LLC (58.7%) and Goldman Sachs Group Inc. (331.1%).

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.98) per share for the quarter.

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.09). On average, analysts expect Tectonic Therapeutic to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Tectonic Therapeutic Stock Performance

Shares of TECX traded up $0.39 during mid-day trading on Friday, reaching $22.31. The company had a trading volume of 369,780 shares, compared to its average volume of 268,589. Tectonic Therapeutic has a 52 week low of $13.70 and a 52 week high of $61.07. The company has a market capitalization of $416.59 million, a price-to-earnings ratio of -3.05 and a beta of 3.27. The firm has a 50-day moving average price of $21.78 and a 200 day moving average price of $24.00.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on TECX shares. Wall Street Zen cut Tectonic Therapeutic from a "hold" rating to a "sell" rating in a research note on Saturday, July 26th. Truist Financial began coverage on shares of Tectonic Therapeutic in a research report on Monday, July 21st. They set a "buy" rating and a $64.00 price objective on the stock. Mizuho raised their price objective on shares of Tectonic Therapeutic from $51.00 to $85.00 and gave the company an "outperform" rating in a research note on Thursday, May 15th. Raymond James Financial assumed coverage on shares of Tectonic Therapeutic in a research note on Wednesday, June 11th. They issued an "outperform" rating and a $76.00 target price on the stock. Finally, Lifesci Capital began coverage on shares of Tectonic Therapeutic in a report on Friday, June 6th. They set an "outperform" rating and a $87.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Tectonic Therapeutic currently has an average rating of "Moderate Buy" and an average target price of $80.33.

Hedge Funds Weigh In On Tectonic Therapeutic

A number of hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its stake in shares of Tectonic Therapeutic by 242.5% in the second quarter. Geode Capital Management LLC now owns 272,257 shares of the company's stock worth $5,411,000 after acquiring an additional 192,770 shares during the period. Jane Street Group LLC lifted its position in Tectonic Therapeutic by 58.7% during the first quarter. Jane Street Group LLC now owns 47,145 shares of the company's stock valued at $835,000 after purchasing an additional 17,443 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Tectonic Therapeutic by 331.1% in the first quarter. Goldman Sachs Group Inc. now owns 104,793 shares of the company's stock worth $1,856,000 after purchasing an additional 80,483 shares during the last quarter. Finally, Millennium Management LLC grew its position in Tectonic Therapeutic by 726.4% in the 1st quarter. Millennium Management LLC now owns 237,938 shares of the company's stock worth $4,214,000 after purchasing an additional 209,145 shares during the period. Hedge funds and other institutional investors own 62.63% of the company's stock.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.